Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C

Head and Neck

Volumn 26, Issue 10, 2004, Pages 845-853

  Christiansen, Hans ^a   Hermann, Robert M ^a   Hille, Andrea ^a   Weiss, Elisabeth ^a   Nitsche, Mirko ^a   Martin, Alexios ^b   Hess, Clemens F ^a   Pradier, Olivier ^a  

^a Department of Radiation Oncology ^*  (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Head and neck cancer; Hemoglobin; Mitomycin C; Prognostic factors; Radiochemotherapy

Indexed keywords

FLUOROURACIL; HEMOGLOBIN; MITOMYCIN C;

ADULT; AGED; ANEMIA; ARTICLE; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEMOGLOBIN DETERMINATION; HOARSENESS; HUMAN; HYPOPHARYNX CARCINOMA; INOPERABLE CANCER; LARYNX CARCINOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MUCOSA INFLAMMATION; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SKIN TOXICITY; SURVIVAL RATE; THROMBOCYTOPENIA; TRISMUS; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 4644282237     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20030     Document Type: Article

References (45)

1. nd ed. Philadelphia: Lippincott Williams & Wilkins; 1994.
2. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996;14:838-847.
3. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-955.
4. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579-589.
5. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831-838.
6. Adam MF, Gabalski EC, Bloch DA, et al. Tissue oxygen distribution in head and neck cancer patients. Head Neck 1999;2:146-153.
7. Rockwells S. Use of hypoxia-directed drugs in the therapy of solid tumors. Semin Oncol 1992;19:29-40.
8. Sartorelli AC, Hodnick WF, Belcourt MF, et al. Mitomycin C: a prototype bioreductive agent. Oncol Res 1994;6:501-508.
9. Budach W, Paulsen F, Welz S, et al. Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer 2002;86:470-476.
10. Pradier O, Eberlein K, Weiss E, Jackel MC, Hess CF. Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluoruracil for inoperable head and neck cancer. Br J Radiol 2001;74:368-374.
11. International Commission on Radiation Units and Measurements. Prescribing, recording and reporting photon beam therapy. ICRU report No. 50, Bethesda, MD: ICRU; 1993.
12. Rubin P, Constine LS III, Fajardo LF, Phillips TL, Wasserman TH. EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system. Radiother Oncol 1995;35:9-10.
13. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;58:457-481.
15. Overgaard J, Hansen HS, Andersen AP, et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989;16:1065-1068.
16. Fein DA, Lee WR, Hanlon AL, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13:2077-2083.
17. Grant DG, Hussain A, Hurman D. Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol 1999;113:829-833.
18. Skladowski K, Tarnawski R, Maciejewski B, Wygoda A, Slasared K. Clinical radiobiology of glottic T1 squamous-cell carcinoma. Int J Radiat Oncol Biol Phys 1999;43:101-106.
19. Stadler P, Becker A, Feldmann HJ, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749-754.
20. Dietz A, Rudat V, Conradt C, et al. Prognostic value of hemoglobin level for primary radiochemotherapy of head-neck carcinomas. HNO 2000;48:655-664.
21. Daly T, Poulsen MG, Denham JW, et al. The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2003;68:113-122.
22. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
23. Staar S, Rudat V, Stuetzner H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-1171.
24. Kies MS, Haraf DJ, Rosen F, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001;19:1961-1969.
25. Karasawa K, Shinoda H, Katsui K, et al. Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. Anticancer Res 2002;22:3785-3788.
26. Haddad R, Colevas AD, Tishler R, et al. Docetaxel, cisplatin, and 5-fluoruracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 2003;97:412-418.
27. Keane TJ, Harwood AR, Elhakim T, et al. Radical radiation therapy with 5-fluoruracil infusion and mitomycin-c for oesophageal squamous carcinoma. Radiother Oncol 1985;4:205-210.
28. Ludgate SM, Crandon AJ, Hudosn CN, Walker Q, Langlands AO. Synchronous 5-fluoruracil, mitomycin-c and radiation therapy in the treatment of locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1988;15:893-899.
29. Cummings B, Keane T, Thomas G, Harwood A, Rider W. Results and toxicity of the treatment of anal carcinoma by radiation therapy or radiation therapy and chemotherapy. Cancer 1984;54:2062-2068.
30. Dinges S, Budach V, Stuschke M, et al. Chemo-radiotherapy for locally advanced head and neck cancer-long term results of a phase II trial. Eur J Cancer 1997;33:1152-1155.
31. Haffty BG, Son YH, Papac R, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. J Clin Oncol 1997;15:268-276.
32. Pradier O, Schmidberger H, Jaeckel M, et al. Adjuvant radiotherapy after transoral microlaser surgery for advanced primary and recurrent squamous cell carcinoma of the head and neck: results of comparative analysis. Radiother Oncol 2002;64:S239.
33. Budach VG, Dinges S, Haake K, et al. Accelerated chemoradiation to 70.6 Gy is more effective than accelerated radiation to 77.6 Gy alone-two years results of a German multicentre randomized trial. Int J Radiat Oncol Biol Phys 2000;48:150-151.
34. Hille A, Rave-Frank M, Pradier O, et al. Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro. Int J Radiat Biol 2003;79:119-128.
35. th ed. New York Toronto: Wiley-Liss; 1997.
36. Keane TJ, Cummings BJ, O'Sullivan B, et al. A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys 1993;25:613-618.
37. Smid L, Lesnicar H, Zakotnik B, et al. Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer-preliminary report. Int J Radiat Oncol Biol Phys 1995;32:769-775.
38. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086.
39. Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000;88:876-883.
40. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-1324.
41. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
42. Dobrowsky W, Naude J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 2000;57:119-124.
43. Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-241.
44. Cummings B, O'Sullivan B, Keane T, et al. A prospective randomized trial of hyperfractionated versus conventional once daily radiation for advanced squamous cell carcinomas of larynx and pharynx-5 year results. Int J Radiat Oncol Biol Phys 2000;48:S151.
45. Fu KK, Pajak TF, Trotti A, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.